Search Within

Population Sciences Research Program

  1. "Andrew Zelenetz"
  2. "2017"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (15)
  2. Department of Medicine (15)
  3. Hematologic Malignancies, Division of (15)
  4. Lymphoma (15)
  5. Survivorship Research (15)
  6. Executive Committee, Center for Hematologic Malignancies (13)

More Groups

People
  1. Andrew Zelenetz (15)
  2. Steven Horwitz (14)
  3. Anas Younes (13)
  4. John Gerecitano (13)
  5. Matthew Matasar (13)
  6. Paul Hamlin (13)

More People

Years
  1. 2017 (15)
Publications
  1. Blood (6)
  2. Hematological Oncology (4)
  3. Clinical Cancer Research (1)
  4. Clinical Lymphoma, Myeloma and Leukemia (1)
  5. Journal of Clinical Oncology (1)
  6. Journal of the National Comprehensive Cancer Network (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. Wiley Blackwell (4)
  3. American Association for Cancer Research (1)
  4. American Society of Clinical Oncology (1)
  5. BMJ Publishing Group Ltd. (1)
  6. Elsevier Inc. (1)

More Publishers

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
    Journal Article

    Bernatsky, S.; Garcia, H. A. V.; Spinelli, J. J.; Gaffney, P.; Smedby, K. E.; Ramsey-Goldman, R.; Wang, S. S.; Adami, H. O.; Albanes, D.; Angelucci, E.; more...
    Lupus Science & Medicine (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse
    Meeting Abstract

    Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Active surveillance for newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
    Meeting Abstract

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C.; Caron, P.; Drullinsky, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save